MARKET

GBS

GBS

GBS Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.100
+0.130
+4.38%
After Hours: 3.130 +0.03 +0.97% 19:38 05/18 EDT
OPEN
3.000
PREV CLOSE
2.970
HIGH
3.130
LOW
2.935
VOLUME
652.82K
TURNOVER
--
52 WEEK HIGH
14.24
52 WEEK LOW
2.935
MARKET CAP
31.65M
P/E (TTM)
-3.9754
1D
5D
1M
3M
1Y
5Y
GBS reports Q1 results
GBS (GBS): Q1 GAAP EPS of -$0.27.Cash, cash equivalents, and marketable securities of $14.2M.Press Release
Seekingalpha · 4d ago
BRIEF-GBS Inc - Qtrly Loss Per Share Of $0.27
reuters.com · 4d ago
GBS Q1 EPS $(0.27) Down From $(0.01) YoY
GBS (NASDAQ:GBS) reported quarterly losses of $(0.27) per share. This is a 2600 percent decrease over losses of $(0.01) per share from the same period last year.
Benzinga · 4d ago
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
- Anticipate Emergency Use Submission for SARS-CoV-2Antibody Biosensor Test in the Second Half of 2021- - $14 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2021, Provides Runway into the Second Half of 2022 - - Established a ...
GlobeNewswire · 4d ago
-- Earnings Flash (GBS) GBS Posts Q1 Revenue $34,290
MT Newswires · 4d ago
ATVI, TEVA, AYX and LYFT among notable premarket gainers
Chiasma CHMA +39% on Q1 results.Athenex ATNX +31% on Kuur Therapeutics acquisition.Ault Global Holdings DPW +30% on preliminary Q1 results.iBio IBIO +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation BGFV +22% on Q1 results.DAVIDsT...
Seekingalpha · 05/05 12:24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 05/05 12:08
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Athenex, Inc. (NASDAQ: ATNX) shares rose 46.6% to $5.44 in pre-market trading after the company announced it acquired Kuur Therapeutics.
Benzinga · 05/05 11:08
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GBS. Analyze the recent business situations of GBS Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About GBS
GBS Inc. is a biosensor diagnostic technology company. The Company develops and commercializes a range of biosensor-based point of care (POCT) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Its flagship product candidate is the Saliva Glucose Biosensor (SGB), a POCT designed to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. SGB uses saliva to measure glucose non-invasively. When the SGB interacts with saliva, an electrochemical reaction is initiated that produces an electrical signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time saliva glucose reading by a software application on a smart device or a dedicated smart reader. The Company is also developing a real-time SARS-CoV-2 antibody biosensor.

Webull offers kinds of Gbs Inc stock information, including NASDAQ:GBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBS stock methods without spending real money on the virtual paper trading platform.